- A systematic review suggests that imatinib is associated with a >60% response rate for patients with locally advanced or metastatic dermatofibrosarcoma protuberans (DFSP).
- ~55% of patients achieved a partial response.
Why this matters
- Existing data on the optimal dose and effectiveness of imatinib are limited and variable.
- The complete response rate was 5.2%.
- The partial response rate was 55.2%.
- The stable disease rate was 27.6%.
- The progression rate was 9.2%.
- 400- and 800-mg daily doses of imatinib were associated with similar response rates (67.5% vs 67.1%; P>.99).
- 60.3% of patients underwent surgery after imatinib.
- 73.5% of patients experienced adverse events, with 15.1% experiencing grade 3/4 adverse events.
- 9 studies with 152 patients treated with imatinib as monotherapy or as adjuvant/neoadjuvant therapy to surgery were included in the systematic review.
- Funding: National Cancer Institute/NIH.
- Heterogeneity between included studies.
- Moderate/high risk for bias in included studies.